DLA Piper has announced that it represented Nexvet Biopharma (Nasdaq: NVET), a clinical-stage biopharmaceutical company focusing on companion animals, in its US$40 million initial public offering.

The DLA Piper team representing Nexvet Biopharma included partners Marjorie Sybul Adams (New York) and Andrew Ledbetter (Seattle), and associates Rachel Worth and Kerra Melvin (both Seattle), with DLA Piper senior counsel Bruce W. Jenett (Silicon Valley) overseeing the Nexvet Biopharma relationship.

BofA Merrill Lynch and Cowen and Company acted as joint lead book-running managers for the offering. Piper Jaffray and JMP Securities acted as co-managers.

Over the past five years, DLA Piper has represented clients in approximately 245 public offerings (equity and debt) in the United States, including 40 IPOs, raising more than $87 billion. In addition, during this time DLA Piper has represented clients in nearly 3,000 venture capital financings and 540 private equity and other private offering transactions in the US totaling over $74 billion.